Aims-To assess whether r-HuEPO (recombinant human erythropoietin) has any effect on thrombopoiesis in patients with chronic renal failure.
Methods-This was a retrospective study of 78 patients with chronic renal failure undergoing either haemodialysis (n = 57) or intraperitoneal dialysis (n = 21). All patients had a full blood count (in EDTA) me before stling r-HuEPO and at monthly intervals thereafter up to six months. Variables studied were haematocrit, platelet count, mean platelet volume (MPV) and platelet distribution width (PDW). Other groups of control patients were also studiedpatients with chronic renal failure receiving dialysis but not r-HuEPO (n = 40) and a group of patients with normal renal function who were receiving aspirin (n = 30).
Results-There was a significant increase in mean haematocrit (p < 0.01) and in mean platelet volume (p < 0-001) over the six month period, but no change in either total platelet count or platelet distribution width in the patients with chronic renal fiilure receiving r-HuEPO. In contrast, both the control groups showed no significant change in The dose of r-HuEPO began at 50 IU/kg twice weekly (by subcutaneous injection), increasing to 75 IU/kg twice weekly after two to three months if there was an insufficient rise in haematocrit and haemoglobin. It is the policy of the renal unit to give aspirin to all patients starting r-HuEPO. Twelve out of the 78 patients did not receive aspirin during the six month period of study as they had been given r-HuEPO before the establishment of this policy.
All the patients had a full blood count (in EDTA) measured on a Coulter STKS (Coulter Electronics, Northwell Drive, Luton, Beds) at monthly intervals from baseline (before starting r-HuEPO) up to six months. As a result of organisational procedure both within the renal wards and the haematology laboratory, most of the samples would have been analysed within 4 hours of venepuncture, but we cannot exclude a few samples having been analysed at a later time.
The variables studied were haematocrit, platelet count, mean platelet volume (MPV) and platelet distribution width (PDW).
Changes in these variables were compared with baseline values and statistically analysed using Student's paired t test. A measure of the difference between the maximum value of a variable achieved over the six month period and baseline was calculated and used in the 7.0 -J -seem to be dependent on a rise in haematocrit under the effect of r-HuEPO as shown by the group of patients with a small rise in haematocrit but with a similar increase in MPV as the others. MPV increased to the same extent under both the lower and higher doses of r-HuEPO, suggesting that there is not a linear dose dependent response. Chronic renal failure is associated with impaired haemostasis manifest in decreased platelet aggregation and prolonged bleeding times.'2 Because larger platelets are more reactive and have been reported to be associated with both cerebral"5 and myocardial infarction'0 16 we suggest that the increase in MPV shown in this study may be one factor in the correction of the haemostatic defect of chronic renal failure and the increased risk of thrombosis which is now recognised as a side effect of r-HuEPO. Platelet volume is seen as a variable that relates to haemostatic function'7 and larger platelets are known to produce more thromboxane A2,9 contain denser granules, and secrete more serotonin andf,-thromboglobulin compared with those of smaller size, while larger platelets are known to aggregate preferentially in the presence of adenosine diphosphate. '8 It used to be believed that larger platelets were younger platelets and that r-HuEPO had a simple thrombopoietin-like action6 12 19 20 resulting in increased numbers of younger and therefore larger platelets. The process of platelet production is still not fully understood, but platelets seem to be produced by fragmentation of the megakaryocyte2'; they do not seem to change in size as they age, and mean platelet volume (MPV) is determined at the time of megakaryocyte fragmentation into platelets. '3 Platelet production and megakaryocyte regulation seem to occur at multiple cellular levels2223 and some cytokines are involved in the proliferative process, others with maturation.22 Several haemopoietic growth factors-interleukin-3, interleukin-6, interleukin 11, LIF (leukaemia inhibitory factor), KL (C-Kit ligand) and EPO itself-stimulate maturation of megakaryocytes which subsequently show increased size, number, and ploidy,'422429 but there have been no reports on the size of platelets produced. Recent work has shown the existence of receptors for EPO on the megakaryocytes of rats and mice" 12 and it is possible that these are also present in man.
Our findings suggest that r-HuEPO acts as a cytokine via receptors on the megakaryocyte and that this action is manifest in the increase in MPV. If this is so, r-HuEPO does not seem to be acting as a simple "thrombopoietin"-like factor as we could show no increase in platelet count. In our study platelet count seems to be independent of platelet size, suggesting that r-HuEPO acts stochastically on megakaryocytes to produce larger platelets.
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